GlassScriptPhysician profile
Kevin Bowman
NPI 1225299829
$2,240.18
in general payments reported to CMS, 2019-2025
21 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $183 · 2021: $387 · 2022: $227 · 2023: $244 · 2024: $250 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,095.49 | 2019-2025 | Clareon, Clareon Panoptix Pro, Lensx |
| Novartis Pharmaceuticals Corporation | $169.50 | 2019-2023 | |
| Biotissue Holdings INC. | $151.28 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $150.63 | 2020-2023 | Cequa |
| Ocular Therapeutix, INC. | $88.80 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $83.24 | 2024 | Tecnis Simplicity |
| Heidelberg Engineering, INC. | $82.94 | 2021 | |
| Oyster Point Pharma, INC. | $65.76 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $58.70 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $51.82 | 2019-2021 | |
| Merz North America, INC. | $41.38 | 2019 | |
| Harrow Eye, LLC | $39.34 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $32.83 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $19.66 | 2024 | Xdemvy |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.04 | 2019 | |
| Glaxosmithkline, LLC. | $16.07 | 2025 | Blenrep |
| Allergan, INC. | $14.98 | 2020 | |
| Omeros Corporation | $14.40 | 2019 | |
| Akorn Operating Company LLC | $14.27 | 2021 | |
| Aerie Pharmaceuticals, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.